We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
- Authors
Lee, Yun‐Gyoo; Kim, Inho; Yoon, Sung‐Soo; Park, Seonyang; Cheong, June Won; Min, Yoo Hong; Lee, Jeong‐Ok; Bang, Soo‐Mee; Yi, Hyeon Gyu; Kim, Chul Soo; Park, Yong; Kim, Byung‐Soo; Mun, Yeung‐Chul; Seong, Chu‐Myoung; Park, Jinny; Lee, Jae Hoon; Kim, Sung‐Yong; Lee, Hong Ghi; Kim, Yeo‐Kyeoung; Kim, Hyeoung‐Joon
- Abstract
The present study aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndromes ( MDS). We compared the overall response rate ( ORR) (complete responses, partial responses, marrow complete responses, and haematological improvements), overall survival ( OS), event-free survival ( EFS), time to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias in this observational study, adjustments were made using the propensity-score matching method. Among 300 patients, 203 were treated with azacitidine and 97 with decitabine. Propensity-score matching yielded 97 patient pairs. In the propensity-matched cohort, there were no significant differences between the azacitidine and decitabine groups regarding ORR (44% vs. 52%), OS (26 vs. 22·9 months), EFS (7·7 vs. 7·0 months), and rate of leukaemic transformation (16% vs. 22% at 1 year). In patients ≥65 years of age, survival was significantly better in the azacitidine group ( P = 0·017). Patients who received decitabine experienced more frequent episodes of grade 3 or 4 cytopenia and infectious episodes. We found that azacitidine and decitabine showed comparable efficacy. Among patients ≥65 years of age, survival was significantly better in the azacitidine group (ClinicalTrials.gov Identifier: NCT01409070).
- Subjects
MYELODYSPLASTIC syndromes treatment; AZACITIDINE; DECITABINE; HEMATOPOIETIC stem cell transplantation; DNA methylation
- Publication
British Journal of Haematology, 2013, Vol 161, Issue 3, p339
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.12256